97 related articles for article (PubMed ID: 12901153)
1. Clinical applications of molecular monitoring in leukemia.
Maslak P
Curr Hematol Rep; 2003 Jan; 2(1):43-8. PubMed ID: 12901153
[TBL] [Abstract][Full Text] [Related]
2. [Genetic tests for leukemia].
Kitamura K
Rinsho Byori; 2002 Nov; Suppl 123():89-97. PubMed ID: 12652795
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of minimal residual disease in leukemia, advantages and pitfalls.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Ann Med; 2006; 38(7):512-21. PubMed ID: 17101542
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of minimal residual disease in chronic myeloid leukemia.
Faderl S; Hochhaus A; Hughes T
Hematol Oncol Clin North Am; 2004 Jun; 18(3):657-70, ix-x. PubMed ID: 15271398
[TBL] [Abstract][Full Text] [Related]
5. [Clinical use of polymerase chain reaction in diagnosis and monitoring of malignant diseases].
Jäger U; Laczika K; Scholten C; Mitterbauer M; Novak M; Lechner K
Wien Klin Wochenschr; 1996; 108(20):634-9. PubMed ID: 9005678
[TBL] [Abstract][Full Text] [Related]
6. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.
Cazzaniga G; Biondi A
Haematologica; 2005 Mar; 90(3):382-90. PubMed ID: 15749670
[TBL] [Abstract][Full Text] [Related]
7. Detection and monitoring of minimal residual disease by quantitative real-time PCR.
Schüler F; Dölken G
Clin Chim Acta; 2006 Jan; 363(1-2):147-56. PubMed ID: 16154122
[TBL] [Abstract][Full Text] [Related]
8. [Childhood acute leukemia: current status and future perspectives in MRD-based therapy].
Tsurusawa M
Rinsho Ketsueki; 2005 Feb; 46(2):109-20. PubMed ID: 16447704
[No Abstract] [Full Text] [Related]
9. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.
Breccia M; Diverio D; Noguera NI; Visani G; Santoro A; Locatelli F; Damiani D; Marmont F; Vignetti M; Petti MC; Lo Coco F
Haematologica; 2004 Jan; 89(1):29-33. PubMed ID: 14754603
[TBL] [Abstract][Full Text] [Related]
10. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
[TBL] [Abstract][Full Text] [Related]
11. The detection and significance of minimal residual disease in acute and chronic leukemia.
Chung NG; Buxhofer-Ausch V; Radich JP
Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250
[TBL] [Abstract][Full Text] [Related]
12. [Modern leukemia diagnosis in adults].
Heilmeier B; Spiekermann K; Bohlander S; Buske C; Feuring-Buske M; Schneider S; Hiddemann W; Braess J
Dtsch Med Wochenschr; 2009 Jun; 134(23):1222-6. PubMed ID: 19472094
[TBL] [Abstract][Full Text] [Related]
13. Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies.
Jilani I; Keating M; Day A; William W; Kantarjian H; O'brien S; Giles FJ; Albitar M
Clin Lab Haematol; 2006 Oct; 28(5):325-31. PubMed ID: 16999724
[TBL] [Abstract][Full Text] [Related]
14. [Minimal residual disease in childhood acute leukemias].
Pawińska K; Balwierz W; Baran J
Przegl Lek; 2006; 63(1):41-3. PubMed ID: 16892899
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Haferlach C; Haferlach T; Schnittger S
Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
[TBL] [Abstract][Full Text] [Related]
16. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
17. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
18. Detecting PML-RARalpha transcript in acute promyelocytic leukemia using real-time quantitative RT-PCR.
Zhu HH; Liu YR; Qin YZ; Jiang B; Shan FX; Wu SL; Yang PD; Zhao J; Lu DP
Chin Med J (Engl); 2007 Oct; 120(20):1803-8. PubMed ID: 18028775
[TBL] [Abstract][Full Text] [Related]
19. [Id4 gene methylation for detection of minimal residual disease in acute leukemia].
Zhao Y; Yu L; Wang QS; Li HH; Bo J; Wang SH; Jin HJ; Lou FD
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):298-301. PubMed ID: 16875575
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling for the diagnosis of acute leukaemia.
Haferlach T; Kohlmann A; Bacher U; Schnittger S; Haferlach C; Kern W
Br J Cancer; 2007 Feb; 96(4):535-40. PubMed ID: 17146476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
